MacroGenics vs Precigen
MGNX and PGEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MGNX and PGEN compare
Precigen is the larger company, worth 12 times as much as MacroGenics ($1.5B against $131M).
MacroGenics scores higher on the StockData Score (5 against 2 for Precigen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MGNX | PGEN |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $1.5B |
| Share price | $2.05 | $4.29 |
| Change, 1 year | 36.7% | −11.5% |
| Change, 5 years | −89.1% | 11.1% |
| Beta (5Y) | 0.53 | 1.20 |
| Employees | 293 | 20 |
| StockData Score | ||
| Total score | 5 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× | – |
| P/B | 3.0× (better) | 35.2× |
| FCF yield | −50.2% | −7.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.7% | – |
| Revenue growth, 5Y average | 7.3% (better) | −21.3% |
| Profitability | ||
| Operating margin | −24.3% | – |
| Net margin | −8.7% | – |
| FCF margin | −39.1% | – |
| Return on equity | −32.6% (better) | −4640% |
| Financial health | ||
| Debt / equity | – | 2.15 |
| Interest coverage | −2.4× | – |
| Current ratio | 2.96 | 4.58 (better) |
| Altman Z-score | −4.02 (better) | −11.14 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 76.4% | 39.2% |
| Held by insiders | 6.2% | 44.9% |
| Insider net buying, 12 months | −$129K (better) | −$32.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 8.3% | 22.8% |
Go deeper
- MGNX stock overview
- MGNX income statement
- MGNX valuation and score
- PGEN stock overview
- PGEN income statement
- PGEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.